BioFirst is planning on constructing a GMP medical device premise.BioFirst captures 25-billion future business opportunities with its liver fibrosis diagnosis system.

The emerging stock company BioFirst, a medical devices factory, which acts as exclusive agent of French company BioPredictive pronounced that the non-invasive liver fibrosis diagnostic system of FibroTest and FibroMax has been widely used in over 50 countries in the whole world. It would occupy the potential business market of 25 billion NT dollars. The general manager of BioFirst, Dr. Tsung-Shann Jiang, expressed that hepatopathy is common in Chinese area. Liver cancer and liver cirrhosis are not easily be detected at early stage. Liver fibrosis evaluation system prevents liver cancer and liver cirrhosis, in addition to the fatty liver patients who are at high risk of liver fibrosis should be regularly evaluated. According to the Ministry of Health and Welfare, there are about 5 million people should take the liver detection in Taiwan. With the fee of 5 thousand per detection, it has potential value of 25 billion NT dollars. Dr. Tsung-Shann Jiang indicated that these two products, FibroTest and FibroMax, are necessary indicators of hepatitis B, hepatitis C, alcoholic Fatty Liver and fatty liver patients who prevent liver cirrhosis and liver cancer. With non-invasive evaluation, blood sample collecting and calculating data, which sent to French database, it can get the result of detection.